Cypher in Japan
This article was originally published in The Gray Sheet
Executive Summary
J&J/Cordis will begin distributing the sirolimus-eluting coronary stent mid-year, co-marketed by Guidant, following Japanese marketing approval, the firm announces March 31. The release will coincide with anticipated reimbursement approval. Japan's Ministry of Health, Labor & Welfare recently lowered reimbursement levels for catheters for cardiac surgery with stents (1"The Gray Sheet" March 1, 2004, p. 27). Approximately 166,000 angioplasties are performed annually in Japan, 70% with stent placement, according to the firm...
You may also be interested in...
Boston Scientific Taxus Japan Launch Delayed Until Second Half Of 2006
Boston Scientific will begin a required Japanese premarket approval trial next year for its Taxus paclitaxel-eluting stent, incorporating a short-term endpoint of major adverse coronary events (MACE)
Japanese Price Revision Cycle Yields Progress Amidst Obstinacy – AdvaMed
U.S. device industry reps expect Japanese "R-zone" price cuts to more closely approximate market conditions than foreign average pricing (FAP) revisions
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.